Skip to main content
Top
Published in: Current Rheumatology Reports 1/2010

Open Access 01-02-2010

Antibodies to Serine Proteases in the Antiphospholipid Syndrome

Authors: Pojen P. Chen, Ian Giles

Published in: Current Rheumatology Reports | Issue 1/2010

Login to get access

Abstract

It is generally accepted that the major autoantigen for antiphospholipid antibodies (aPL) in the antiphospholipid syndrome (APS) is β2-glycoprotein I (β2GPI). However, a recent study has revealed that some aPL bind to certain conformational epitope(s) on β2GPI shared by the homologous enzymatic domains of several serine proteases involved in hemostasis and fibrinolysis. Importantly, some serine protease–reactive aPL correspondingly hinder anticoagulant regulation and resolution of clots. These results extend several early findings of aPL binding to other coagulation factors and provide a new perspective about some aPL in terms of binding specificities and related functional properties in promoting thrombosis. Moreover, a recent immunological and pathological study of a panel of human IgG monoclonal aPL showed that aPL with strong binding to thrombin promote in vivo venous thrombosis and leukocyte adherence, suggesting that aPL reactivity with thrombin may be a good predictor for pathogenic potentials of aPL.
Literature
1.
go back to reference Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295–306.CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295–306.CrossRefPubMed
2.
go back to reference Bertolaccini ML, Khamashta MA, Hughes GR: Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005, 1:40–46.CrossRefPubMed Bertolaccini ML, Khamashta MA, Hughes GR: Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005, 1:40–46.CrossRefPubMed
3.
go back to reference Pierangeli SS, Chen PP, Raschi E, et al.: Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008, 34:236–250.CrossRefPubMed Pierangeli SS, Chen PP, Raschi E, et al.: Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008, 34:236–250.CrossRefPubMed
4.
go back to reference Lockshin MD, Derksen RH: New developments in lupus-associated antiphospholipid syndrome. Lupus 2008, 17:443–446.CrossRefPubMed Lockshin MD, Derksen RH: New developments in lupus-associated antiphospholipid syndrome. Lupus 2008, 17:443–446.CrossRefPubMed
5.
go back to reference Pierangeli SS, Stewart M, Silva LK, Harris EN: An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998, 25:156–160.PubMed Pierangeli SS, Stewart M, Silva LK, Harris EN: An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998, 25:156–160.PubMed
6.
go back to reference Brandt JT, Barna LK, Triplett DA: Laboratory identification of lupus anticoagulants: results of the Second International Workshop for identification of lupus anticoagulants. On behalf of the subcommittee on lupus anticoagulants antiphospholipid antibodies of the ISTH. Thromb Haemost 1995, 74:1597–1603.PubMed Brandt JT, Barna LK, Triplett DA: Laboratory identification of lupus anticoagulants: results of the Second International Workshop for identification of lupus anticoagulants. On behalf of the subcommittee on lupus anticoagulants antiphospholipid antibodies of the ISTH. Thromb Haemost 1995, 74:1597–1603.PubMed
7.
go back to reference Fleck RA, Rapaport SI, Rao LV: Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988, 72:512–519.PubMed Fleck RA, Rapaport SI, Rao LV: Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988, 72:512–519.PubMed
8.
go back to reference McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990, 87:4120–4124.CrossRefPubMed McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990, 87:4120–4124.CrossRefPubMed
9.
go back to reference Oosting JD, Derksen RH, Bobbink IW, et al.: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993, 81:2618–2625.PubMed Oosting JD, Derksen RH, Bobbink IW, et al.: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993, 81:2618–2625.PubMed
10.
go back to reference Permpikul P, Rao LV, Rapaport SI: Functional and binding studies of the roles of prothrombin and b2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994, 83:2878–2892.PubMed Permpikul P, Rao LV, Rapaport SI: Functional and binding studies of the roles of prothrombin and b2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994, 83:2878–2892.PubMed
11.
go back to reference Branch DW, Dudley DJ, Mitchell MD, et al.: Immunoglobulin G fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990, 163:210–216.PubMed Branch DW, Dudley DJ, Mitchell MD, et al.: Immunoglobulin G fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990, 163:210–216.PubMed
12.
go back to reference Pierangeli SS, Colden-Stanfield M, Liu XW, et al.: Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997–2002.PubMed Pierangeli SS, Colden-Stanfield M, Liu XW, et al.: Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997–2002.PubMed
13.
go back to reference Cariou R, Tobelem G, Bellucci S, et al.: Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988, 60:54–58.PubMed Cariou R, Tobelem G, Bellucci S, et al.: Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988, 60:54–58.PubMed
14.
go back to reference Marciniak E, Romond EH: Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989, 74:2426–2432.PubMed Marciniak E, Romond EH: Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989, 74:2426–2432.PubMed
15.
go back to reference Borrell M, Sala N, de Castellarnau C, et al.: Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992, 68:268–272.PubMed Borrell M, Sala N, de Castellarnau C, et al.: Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992, 68:268–272.PubMed
16.
go back to reference Escolar G, Font J, Reverter JC, et al.: Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Arterioscler Thromb 1992, 12:196–200.PubMed Escolar G, Font J, Reverter JC, et al.: Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Arterioscler Thromb 1992, 12:196–200.PubMed
17.
go back to reference Vega-Ostertag M, Harris EN, Pierangeli SS: Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50:2911–2919.CrossRefPubMed Vega-Ostertag M, Harris EN, Pierangeli SS: Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50:2911–2919.CrossRefPubMed
18.
go back to reference Kornberg A, Blank M, Kaufman S, Shoenfeld Y: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994, 153:1328–1332.PubMed Kornberg A, Blank M, Kaufman S, Shoenfeld Y: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994, 153:1328–1332.PubMed
19.
go back to reference Simantov R, LaSala JM, Lo SK, et al.: Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211–2219.CrossRefPubMed Simantov R, LaSala JM, Lo SK, et al.: Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995, 96:2211–2219.CrossRefPubMed
20.
go back to reference Amengual O, Atsumi T, Khamashta MA, Hughes GR: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998, 79:276–281.PubMed Amengual O, Atsumi T, Khamashta MA, Hughes GR: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998, 79:276–281.PubMed
21.
go back to reference Vega-Ostertag M, Casper K, Swerlick R, et al.: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545–1554.CrossRefPubMed Vega-Ostertag M, Casper K, Swerlick R, et al.: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545–1554.CrossRefPubMed
22.
go back to reference Holers VM, Girardi G, Mo L, et al.: Complement c3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211–220.CrossRefPubMed Holers VM, Girardi G, Mo L, et al.: Complement c3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211–220.CrossRefPubMed
23.
go back to reference Pierangeli SS, Girardi G, Vega-Ostertag M, et al.: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120–2124.CrossRefPubMed Pierangeli SS, Girardi G, Vega-Ostertag M, et al.: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120–2124.CrossRefPubMed
25.
26.
go back to reference Bick RL, Kaplan H: Syndromes of thrombosis and hypercoagulability: congenital and acquired causes of thrombosis. Med Clin North Am 1998, 82:409–458.CrossRefPubMed Bick RL, Kaplan H: Syndromes of thrombosis and hypercoagulability: congenital and acquired causes of thrombosis. Med Clin North Am 1998, 82:409–458.CrossRefPubMed
27.
go back to reference Rao LV, Hoang AD, Rapaport SI: Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996, 88:4173–4182.PubMed Rao LV, Hoang AD, Rapaport SI: Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996, 88:4173–4182.PubMed
28.
go back to reference Zhao Y, Rumold R, Zhu M, et al.: An IgG anti-prothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999, 42:2132–2138.CrossRefPubMed Zhao Y, Rumold R, Zhu M, et al.: An IgG anti-prothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 1999, 42:2132–2138.CrossRefPubMed
29.
go back to reference Vega-Ostertag M, Liu X, Kwan-Ki H, et al.: A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006, 135:214–219.CrossRefPubMed Vega-Ostertag M, Liu X, Kwan-Ki H, et al.: A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006, 135:214–219.CrossRefPubMed
30.
go back to reference Pearson JD: Endothelial Cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:329–341.PubMedCrossRef Pearson JD: Endothelial Cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:329–341.PubMedCrossRef
31.
go back to reference Hwang KK, Grossman JM, Visvanathan S, et al.: Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001, 167:7192–7198.PubMed Hwang KK, Grossman JM, Visvanathan S, et al.: Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001, 167:7192–7198.PubMed
32.
go back to reference Pierangeli SS, Liu X, Espinola R, et al.: Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000, 84:388–395.PubMed Pierangeli SS, Liu X, Espinola R, et al.: Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000, 84:388–395.PubMed
33.
go back to reference Hwang KK, Yang CD, Yan W, et al.: A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003, 48:1622–1630.CrossRefPubMed Hwang KK, Yang CD, Yan W, et al.: A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003, 48:1622–1630.CrossRefPubMed
34.
go back to reference Yang CD, Hwang KK, Yan W, et al.: Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004, 172:5765–5773.PubMed Yang CD, Hwang KK, Yan W, et al.: Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004, 172:5765–5773.PubMed
35.
go back to reference Kolev K, Gombas J, Varadi B, et al.: Immunoglobulin g from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002, 87:502–508.PubMed Kolev K, Gombas J, Varadi B, et al.: Immunoglobulin g from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002, 87:502–508.PubMed
36.
go back to reference Tincani A, Spatola L, Prati E, et al.: The anti-b2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native b2-glycoprotein I and preserved during species' evolution. J Immunol 1996, 157:5732–5738.PubMed Tincani A, Spatola L, Prati E, et al.: The anti-b2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native b2-glycoprotein I and preserved during species' evolution. J Immunol 1996, 157:5732–5738.PubMed
37.
go back to reference Zhu M, Olee T, Le DT, et al.: Characterization of IgG monoclonal anti-cardiolipin/antib2GP1 antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies. Br J Haematol 1999, 105:102–109.CrossRefPubMed Zhu M, Olee T, Le DT, et al.: Characterization of IgG monoclonal anti-cardiolipin/antib2GP1 antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies. Br J Haematol 1999, 105:102–109.CrossRefPubMed
38.
go back to reference Lu CS, Horizon AA, Hwang KK, et al.: Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005, 52:4018–4027.CrossRefPubMed Lu CS, Horizon AA, Hwang KK, et al.: Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005, 52:4018–4027.CrossRefPubMed
39.
go back to reference Cugno M, Cabibbe M, Galli M, et al.: Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004, 103:2121–2126.CrossRefPubMed Cugno M, Cabibbe M, Galli M, et al.: Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004, 103:2121–2126.CrossRefPubMed
40.
go back to reference ••Lin WS, Chen PC, Yang CD, et al.: Some antiphospholipid antibodies recognize conformational epitopes shared by beta(2)-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007, 56:1638–1647. This paper showed that both patient-derived IgG monoclonal anti-β 2 GPI antibodies bind to three serine proteases in hemostasis and that a patient-derived IgG mAb against protein C (P1) reacted with β2GPI. Moreover, P1 binding to β2GPI and thrombin was crossinhibited by both antigens, indicating that the P1 aPL recognizes shared epitope(s) on β 2 GPI and thrombin, which represents the homologous enzymatic domains of several targeted serine protease.CrossRefPubMed ••Lin WS, Chen PC, Yang CD, et al.: Some antiphospholipid antibodies recognize conformational epitopes shared by beta(2)-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007, 56:1638–1647. This paper showed that both patient-derived IgG monoclonal anti-β 2 GPI antibodies bind to three serine proteases in hemostasis and that a patient-derived IgG mAb against protein C (P1) reacted with β2GPI. Moreover, P1 binding to β2GPI and thrombin was crossinhibited by both antigens, indicating that the P1 aPL recognizes shared epitope(s) on β 2 GPI and thrombin, which represents the homologous enzymatic domains of several targeted serine protease.CrossRefPubMed
41.
go back to reference •Chen XX, Gu YY, Li SJ, et al.: Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 2007, 178:5351–5356. This paper showed that plasmin immunization in mice induced pathogenic aPL.PubMed •Chen XX, Gu YY, Li SJ, et al.: Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 2007, 178:5351–5356. This paper showed that plasmin immunization in mice induced pathogenic aPL.PubMed
42.
go back to reference Exner T, Rickard KA, Kronenberg H: A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978, 40:143–151.CrossRefPubMed Exner T, Rickard KA, Kronenberg H: A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978, 40:143–151.CrossRefPubMed
43.
44.
go back to reference Giles I, Rahman A: How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Pract Res Clin Rheumatol 2009, 23:525–537.CrossRefPubMed Giles I, Rahman A: How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Pract Res Clin Rheumatol 2009, 23:525–537.CrossRefPubMed
45.
go back to reference Giles I, Lambrianides N, Pattni N, et al.: Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006, 177:1729–1736.PubMed Giles I, Lambrianides N, Pattni N, et al.: Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006, 177:1729–1736.PubMed
46.
go back to reference ••Giles I, Pericleous C, Liu X, et al.: Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol 2009, 182:4836–4843. This paper shows that the reactivity of a panel of closely related monoclonal aPL with thrombin, most closely predicts their ability to promote thrombosis and activate endothelial cells in a murine model of thrombosis and microcirculation.CrossRefPubMed ••Giles I, Pericleous C, Liu X, et al.: Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol 2009, 182:4836–4843. This paper shows that the reactivity of a panel of closely related monoclonal aPL with thrombin, most closely predicts their ability to promote thrombosis and activate endothelial cells in a murine model of thrombosis and microcirculation.CrossRefPubMed
47.
go back to reference Bertina RM: Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003, 33:395–400.CrossRefPubMed Bertina RM: Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003, 33:395–400.CrossRefPubMed
48.
go back to reference Kottke-Marchant K, Duncan A: Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002, 126:1326–1336.PubMed Kottke-Marchant K, Duncan A: Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002, 126:1326–1336.PubMed
49.
go back to reference Furie B, Bing DH, Feldmann RJ, et al.: Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J Biol Chem 1982, 257:3875–3882.PubMed Furie B, Bing DH, Feldmann RJ, et al.: Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J Biol Chem 1982, 257:3875–3882.PubMed
50.
go back to reference ••Yang YH, Chien D, Wu M, et al.: Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009, 182:1674–1680. This paper demonstrated that some aPL bound to FIXa and hindered inactivation of FIXa by antithrombin and that such FIXa-reactive aPL occurred in 11 of 38 (28.9%) patients with APS tested.PubMed ••Yang YH, Chien D, Wu M, et al.: Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009, 182:1674–1680. This paper demonstrated that some aPL bound to FIXa and hindered inactivation of FIXa by antithrombin and that such FIXa-reactive aPL occurred in 11 of 38 (28.9%) patients with APS tested.PubMed
Metadata
Title
Antibodies to Serine Proteases in the Antiphospholipid Syndrome
Authors
Pojen P. Chen
Ian Giles
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 1/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-009-0072-7

Other articles of this Issue 1/2010

Current Rheumatology Reports 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.